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ABSTRACT 
Interleukin (IL) -22 is a novel mediator of a member of IL-10 family cytokines that is produced by many different types of 
lymphocytes including both those of innate and adaptive immune system. This cytokine has potent proliferative and inflammatory 
effects on different cell lines. Recently, accumulated data has indicated that IL-22 plays an important role in the pathogenesis of 
rheumatoid arthritis (RA). We aimed to investigate the levels of IL-22 and its association with demographic, clinical data as well 
as serological markers in RA. IL-22 serum levels were measured in 45 newly diagnosed RA patients without any treatment and 45 
healthy individuals as control by a manual Enzyme linked immunosorbent assay (ELISA). Correlations of IL-22 serum levels were 
sought with demographic, clinical data and serological parameters. IL-22 levels were significantly elevated in serum of RA 
patients (median= 86.89ng/ml and range = 896) compared to serum of healthy control (median=75.36ng/ml and range=459), 
p=.022. The IL-22 levels were correlated positively with C-reactive protein (CRP), anti-cyclic citrullinated peptide (ACCP) 
antibodies in RA patients. Significant higher levels of serum IL-22 in RA patients compare with those in healthy control. Highly 
significant association between serum levels of IL-22 and the serological markers (CRP and ACCP antibodies) in the diagnosis of 
RA suggest the potential levels of IL-22 as a valuable biomarker for the evaluation of disease severity in RA patients. 
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INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic inflammatory 
disease that represents one of the most common 
autoimmune-related disease. Histologically, it is 
characterized by prominent infiltration of inflammatory 
mononuclear cells, such as T cells and macrophages, 
and the proliferation of synovial fibroblasts
1
.  In RA, it 
is clear that inflammatory cytokines play a key role in 
driving T cell activation and migration that lead to joint 
destruction
2
.  
Interleukin (IL)-22 is a novel α-helical protein, the 
human IL-22 encoding gene is located in the longer 
arm (q15) of chromosome 12
3
.
 
 It belongs to a group of 
cytokines called the IL-10 family which is a class of 
potent mediators of cellular inflammatory responses
4,5
. 
IL-22 differs from other cytokines of IL-10 family by 
being a potent proliferative and inflammatory agent for 
different cell lines
3,6
. Many types of cells from 
lymphoid lineage can secrete IL-22, including both 
those of the innate and adaptive immune system. In 
humans, these cells include activated CD4
+ 
T cells, 
CD8
+ 
T cells
7-9
 and γδ T cells10 as well as various 
innate lymphoid cells such as Natural killer (NK) cells, 
NKT cells
11-13
 lymphoid tissue inducer (LTi) and LTi-
like cells
14
.  Several studies have shown that IL-22 has 
a major role in both defense against certain microbes 
and the development and maintenance of chronic 
inflammatory diseases
15,16
. In addition, it plays an 
important role in mucosal tissue protection and wound 
healing
16,17
. Moreover, it induces proliferative and anti-
apoptotic pathways in responsive cells allowing for 
tissue preservation
18
. 
The IL-22 receptor complex is composed of IL-22R1 
and IL-10R2
19-21
 IL-22R1 subunit is restricted to cell 
lineages of a non-haematopoitic origin, in particular, 
pancreas, kidney and liver as well as barrier surfaces 
such as the skin, intestine and lung
22, 23
. It is important 
to note that the bone marrow, peripheral blood 
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mononuclear cell, spleen, thymus do not express IL-
22R
5, 24
 and therefore immune cells are not targets of 
IL-22
23
. In humans, Th22, a subset of CD
4+ 
T cells that 
specifically express IL-22 is mainly found in tissues
25
. 
Animal models as well as human studies have 
identified both inflammatory 
23, 26
 and protective roles 
for IL-22 in autoimmune diseases
18
. In RA, IL-22 is 
assumed to play a pathogenetic role. However, the 
mechanism by which IL-22 contributes to RA 
pathogenesis is not completely clear. The assumption 
was mainly based on the observed minimally reduced 
susceptibility of the IL-22
-/- 
mice to collagen-induced 
arthritis (CIA) and decreased incidence of pannus 
information. In this model of inflammatory arthritis, 
IL-22 was found to promote osteoclastogenesis and this 
effect may be associated with the reduced severe 
arthritis in IL-22-deficient mice
27
. Previous studies 
suggest that IL-22, through the STAT3, ERKV2, and 
p38 MAKP pathways stimulate synovial fibroblasts 
proliferation and monocyte chemoattractants protein 
(MCP)-1production, leading to inflammation
6,28
. 
Recently, Sakar et al. reported that IL-22 reduces the 
severity of CIA, when administered prior to the onset 
of the disease and showed that the mechanism of which 
is associated with increased with levels of IL-10
29
. 
Other recent study, has been shown that IL-22 
significantly enhanced fibroblast-like synoviocytes 
proliferation in RA and suggests that its contribution to 
the synovium hyperplasia and joint destruction. This 
study showed that potential stimulus present in the 
rheumatoid joint, such as TNF-α and lipo-
polysaccharides are able to induce IL-22 expression
30
. 
A more recent study, reported that IL-22 promoted 
osteoclastogenesis in RA by induction of receptor 
activator of nuclear factor kappa-B ligand (RANKL) in 
human synovial fibroblast
31
. 
This study was conducted to investigate the presence of 
IL-22 in the sera of patients with RA and healthy 
controls and to determine the association between the 
level of IL-22 and the blood parameters including C-
Reactive Protein (CRP), rheumatoid factor (RF), and 
anti-citrullinated-peptide (ACCP) antibodies, as well as 
its association to demographic and clinical data in RA 
cases. 
 
SUBJECTS AND METHODS 
This case-control study was conducted at Al-Thawra 
Modern General Hospital and University of Science 
and Technology Hospital, Sana'a city, Yemen during a 
period of one year starting in April 2015 and ending in 
April 2016. The study group; 45 patients with new 
onset RA were recruited and diagnosed, according  to 
the revised criteria for classification of RA by the 
American College of Rheumatology (ACR) criteria
32
. 
These patients had never been treated with 
immunosuppressive drugs. The control group is 45 
healthy subjects without RA were used as healthy 
controls. The personal and clinical information of 
patients and control are shown in Table 1. We 
conducted the study in accordance with ethical 
standards, and verbal informed consents were obtained 
from all participants before their enrollment. Patients 
were excluded if they had any other autoimmune 
diseases or infection or he/she had received 
immunosuppressive or glucocorticoid therapies within 
the past 6 months.  
Five ml of venous blood was collected from each 
subject. The specimens were allowed to clot at room 
temperature and centrifuged at 3500 rpm for five 
minutes. Serum was separated from each sample into 
three ependroff tubes; one tube for IL-22 test, second 
for RF test and CRP test and the third for ACCP test. 
They stored at -20°C till tested. The sera of the selected 
subjects were tested to determine the IL-22 by a 
commercially available manual enzyme linked 
immunosorbent assay (ELISA), Glory Science Co., 
Ltd, USA]. ACCP antibodies were determined by a 
manual ELISA kit manufactured by (INOVA 
Diagnostics Kits, San Diego, CA-USA). The levels of 
serum CRP, and RF were analyzed by latex tests (Vitro 
Science Co, Egypt). 
 
DATA ANALYSIS 
According to data distribution, the quantitative data 
were expressed as median and range
33
. The 
demographic and clinical data were expressed as 
number and percentage. Independent sample T test was 
used for comparison between the patients and control 
groups. The potential correlation between variables 
was analyzed by the spearman rank correlation test.  
All statistical tests were performed by using the SPSS 
version 20 for windows (SPSS, Inc., Chicago, IL, 
USA) with 95% confidence interval. A two sided p-
value of≤ 0.05 was considered statistically significant. 
 
RESULTS 
The demographic data of healthy control and patients 
showed in Table 1. At presentation, most of patients 
(97.8%) had joint pain and morning stiffness (93.3%), 
while 86.7% had swollen joints and 80% had fatigue. 
Twenty seven patients (60%) had symmetric arthritis, 
19 (42.2%) had fever and only 8 patients (17.8%) had 
family history (Table 2). 
IL-22 levels in serum of RA patients were significantly 
higher compared to that in the healthy control (p= 
.022). As we expected, there were significant 
differences between patients and healthy control in the 
levels of CRP, RF, and ACCP (p=0.000) Table 3.  
Correlational analysis between the serum levels of IL-
22 in the patient and personal and clinical data show no 
significant difference.  As regard serologic parameters, 
a significant positive correlation was found between 
the levels of serum IL-22 and CRP and ACCP 
(rho=.416 p=.004, rho=.559 p=.000, respectively), 
however, there was no significant correlation between 
levels of IL-22 and RF in RA patients (Table 4 and Fig. 
1 and 2, respectively).   
 
DISCUSSION 
IL-22 has been recently suggested to be involved in the 
pathogenesis of autoimmune arthritis. In our study, we 
observed significantly elevated levels of IL-22 in 
serum of RA patients compared to healthy controls 
(p=.022). Our data are in accordance with previous 
reports that found elevation of IL-22 in serum and 
plasma of patients with RA
34-37
. In consistent with our 
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study, IL-22 mRNA was detected in synovial tissue 
directly as well as in synovial fluid mononuclear cells 
in patients with RA
6, 37, 38
. As regard to the sources of 
IL-22 in humans, many studies reported that the higher 
frequency of peripheral IL-22
+
CD
4+
T cells in RA 
patients than those in the controls
36, 39
. Moreover, Zhoa 
et al. showed that IL-22
+
CD4
+
T cells were correlated 
positively with the disease activity in RA patients and 
the percentage of these cells were correlated positively 
with the levels of plasma IL-22 in these patients
36
. 
Another recent study has been shown that the 
synovium in RA patients is infiltrated by T 
lymphocytes especially Th17 which is also a source of 
IL-22
40
. 
Correlation analysis revealed that a significant positive 
correlations between levels of serum IL-22 and CRP 
and ACCP antibodies (rho=.0416, p=.004 and 
rho=.559, p=.000, respectively). In line with our result, 
kim et al. found a significant association between 
serum IL-22 and ACCP antibodies
37
. Of potential 
implication, the strong association of elevated serum 
IL-22 with the more specific serologic marker, ACCP 
antibodies. In addition, many recent studies reported 
that IL-22 has been involved in joint destruction in 
RA
27, 34, 35
 thus, determination of ACCP antibodies and 
IL-22 levels may provide a novel means for predicting 
aggressive disease in these patients. Regarding to the 
correlation between IL-22 levels and RF in RA 
patients, our study showed no significant association 
between them; however, some previous studies 
demonstrated a positive correlation between them
36, 37
. 
While we did not find any previous study about the 
correlation between IL-22 and CRP. 
To our knowledge, there is no report available on the 
correlation between IL-22 and the neither individual 
nor clinical data in RA. In our study, there are no 
correlations between serum IL-22 and neither 
demographic nor clinical data of our patients. In line 
with our observation, disease activity in IL-22 
knockout mice of CIA did not differ from that of their 
wild-type littermates
27
. In addition, recent study 
between high and normal levels of serum IL-22 in early 
untreated RA patients showed no differences in the 
clinical inflammatory parameters of the two groups of 
patients, although these studies showed an association 
between serum IL-22 levels and bone erosin
34, 27
. On 
the other hand, previous studies on patients with RA 
have been a correlation between levels of Il-22 and 
disease activity or severity
35
. However, recent an 
experimental study has been shown that synovial 
inflammation was not affected in IL-22-/- mice and this 
study concludes that the local IL-22 produced by 
adaptive or innate immune cell have no direct 
contribution to the induction of T cell-mediated 
synovial inflammation
29
. Many studies suggest that the 
possible explanation for these differences is depending 
on different phases of the disease development
29, 30, 41
. 
 
CONCLUSION 
In conclusion, our data indicated high levels of IL-22 
in RA patients and that the strong association with 
ACCP antibodies suggests the potential of IL-22 and 
ACCP antibodies levels as predictive markers in this 
disease. It is also of interest that as immune cells do not 
express IL-22, targeting IL-22 and related signaling 
may be an effective therapeutic approach for treating 
autoimmune RA. 
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Table 1: Demographic data of control and cases of RA. 
Demographic data 
 
Healthy 
controls 
(N=45) 
Patients with 
RA 
(N=45) 
P 
 
   Age (years) 
 
Median  
Range                    
Min-Max 
40 
80 
(10-90) 
40 
50 
(10-60) 
.734 
Gender 
Female 
Male 
36 
9 
39 
6 
.402 
Residence 
R 
U 
10 
35 
19 
26 
.043 
Smoking  
habit 
No                       
Yes 
41 
4 
38 
7 
.340 
Qat chewing 
No 
Yes 
30 
15 
32 
13 
.653 
R/U: Rural/ Urban; Probability value (p) ≤0.05 (*: significant) 
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Table 2: The distribution of clinical data among cases of RA. 
Clinical data 
Duration 
(years) 
 
Median 
Min-Max 
Range 
2.0 
(0.16-10) 
9.840 
Family history N (%) 8 (17.8) 
Fever N (%) 19 (42.2) 
Joint pain N (%) 44 (97.8) 
Morning stiffness N (%) 42 (93.3) 
Swollen joints N (%) 39 (86.7) 
Fatigue N (%) 36 (80) 
Symmetric arthritis N (%) 27 (60) 
 
Table 3: The levels of Il-22 and serologic markers of RA in control and cases. 
Parameters Healthy 
controls 
(N=45) 
Patients 
with RA 
(N=45) 
P 
 
IL-22 
(ng/mL) 
Median 
Range              
Min-Max 
75.36 
459 
(55-514) 
86.89 
825 
(56-881) 
0.022
**
 
 
CRP 
(mg/mL) 
Median 
Range                        
Min-Max 
.00 
24 
(0-24) 
24.0 
48 
(0-48) 
 
0.000
**
 
 
RF 
(IU/mL) 
Median 
Range                        
Min-Max 
.00 
32 
(0-320) 
32.0 
64 
(0-64) 
 
0.000
**
 
 
ACCP 
(U/mL) 
Median 
Range                        
Min-Max 
.00 
320 
(0-320) 
221.0 
517 
(0-517) 
 
0.000
**
 
CRP: C-reactive protein; RF: rheumatoid factor; ACCP: anti-cyclic citrullinated peptide. The normal ranges of CRP, RF and CCP, and are 
0–25 U/mL, 0–15 mg/L and 0–15 IU/Ml respectively. Probability value (p) ≤0.05 (*: significant) 
 
 
Table 4: Correlation between the levels of IL-22 and different variables in patients with RA 
 IL-22 (ng/ml) 
(N=45) 
Demographic data 
Age (years) rho=.272, p= .071 
Gender (Female/Male)  rho=.015, p= .922 
Residence (R/U) rho=.121, p= .428 
Smoking habit (%) rho=.012, p= .939 
Qat chewing (%) rho=.098, p= .521 
Clinical data 
Family History (%) rho=.219-, p= .148 
Joints pain (%) rho=.128-, p= .403 
Morning stiffness (%) rho=.144-, p= .0345 
Swelling joints (%) rho=.078-, p= .610 
Fever (%) rho=.097, p= .526 
Fatigue (%) rho=.017, p= .911 
Symmetric arthritis (%) rho=.070-, p= .648 
Duration (years) rho=.280, p= .062 
Serologic parameters 
CRP (mg/mL) rho=.416
**
, p= .004 
RF (IU/mL) rho=.291, p= .053 
ACCP (U/mL) rho=.559
**
, p= .000 
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Figure 1: The correlation between serum levels of IL-22 and CRP in RA patients. 
 
 Figure 2: The correlation between serum levels of IL-22 and ACCP in RA patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
